NSAIDs and COX-2-inhibitors: Current status;NSAR und coxibe: Aktueller stand

Internist

Volumn 47, Issue 5, 2006, Pages 533-540

  Kneitz, C ^a   Tony, H ^a   Kruger K ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Praxiszentrum St Bonifatius   (Germany)

Author keywords

Cardiovascular toxicity; COX 2 inhibitors; Gastrointestinal toxicity; Non steroidal anti inflammatory drugs

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROTON PUMP INHIBITOR; ROFECOXIB; SALICYLIC ACID; VALDECOXIB;

ARTICLE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DRUG SELECTIVITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; PAIN; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; OSTEOARTHRITIS; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SPONDYLITIS, ANKYLOSING;

EID: 33646552119     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1585-z     Document Type: Article

References (44)

1. Aw TJ, Haas SJ, Liew D, Krum H (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165: 490-496
2. Bensen W, Weaver A, Espinoza L et al. (2002) Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology 41: 1008-1016
3. Bolten WW et al. (1999) Konsequenzen und Kosten der NSA-Gastropathie in Deutschland. Akt Rheumatol 24 127-134
4. Bolten WW (2006) Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65: 7-13
5. Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528
6. Bresalier RS, Sandler RS, Quan H et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102
7. Brooks PM, Day RO (1991) Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 324: 1716-1725
8. Coulter DM, Clark DW, Savage RL (2003) Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 327: 1214-1215
9. Dougados M, Behier JM, Jolchine I et al. (2001) Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis. A six week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44: 180-185
10. Dubois RN, Abramson SB, Crofford L et al. (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073
11. Chan FK, Hung LC, Suen BY et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104-2110
12. Fitzgerald G (2004) Coxibs and cardiovascular disease. N Engl J Med 351: 1709-1711
13. Fitzgerald G (2005) Mechanism based adverse cardiovascular events and specific inhibitors of COX-2. http://www.fda.gov/ohrms/dockets/ac/05/ slides/2005-409051_03_FDA-Fitzgerald.ppt
14. Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 115: 787-796
15. Garcia Rodriguez LA, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769-772
16. Giannitsis E (2005) Rationale zur Testung des kardiovaskulären Risikos bei Patienten mit COX-2-Hemmern anhand des Biomarkers NT-proBNP. Clin Lab 51: 73-83
17. Goldstein JL, Eisen GM, Lewis B et al. (2005) Video capsule endoscopy to prospectively assess small bowel injury with, celecoxib, naproxen plus omeprazol, and placebo. Clin Gastroenterol Hepatol 3: 133-141
18. Graham DJ, Campen D, Hui R et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested casecontrol study. Lancet 365: 475-481
19. Hippisley-Cox J, Coupland C, Logan R (2005) Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331: 1310-1312
20. Hudson M, Richard H, Pilote L (2005) Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study BMJ 330: 1370-1376
21. Jones SC (2005) Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother 39: 1249-1259
22. Kimmel SE, Berlin JA, Reilly M et al. (2005) Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142: 157-164
23. Leese PT, Hubbard RC, Karim A et al. (2000) Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 40: 124-132
24. Levesque LE, Brophy JM, Zhang B (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142: 418-419
25. Mamdani M, Rochon P, Juurlink DN et al. (2003) Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction. Arch Intern Med 163: 481-486
26. Meade EA, Smith WL, DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268: 6610-6614
27. Nussmeier NA, Whelton AA, Brown MT et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091
28. Perazella MA, Tray K (2001) Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 111: 64-67
29. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360: 1071-1073
30. Schneider F, Meziani F, Chartier C et al. (2002) Fatal allergic vasculitis associated with celecoxib. Lancet 359: 852-853
31. Schnitzer TJ, Beier J, Geusens P et al. (2004) Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 51: 549-557
32. Schnitzer TJ, Burmester GR, Mysler E et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665-674
33. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH (2005) Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX-2inhibitiors and myocardial infarction. Epidemiology 16: 17-24
34. Shapiro LE, Knowles SR, Weber E et al. (2003) Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf 26: 187-195
35. Sheehan KM, Sheahan K, O'Donoghue DP et al. (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282: 1254-1257
36. Silverstein FE, Faich G, Goldstein JL et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 284: 1247-1255
37. Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol 26 [Suppl]: 18-24
38. Solomon DH, Schneeweiss S, Glynn RJ et al. (2004) Relationship between selective COX-2 inhibitors and acute myocardial infarction. Circulation 109: 2068-2073
39. Solomon DH (2005) Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 52: 1968-1978
40. Solomon SD, McMurray JV, Pfeffer MA et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080
41. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nat New Biol 231: 232-235
42. Wiesenhutter CW, Boice JA, Ko A et al. (2005) Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80: 470-479
43. FDA (2005) Cardiovascular safety and risk-benefit assessment. http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex- Bextra.pdf
44. NIH (2004) Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. http://www.nih.gov/news/pr/ dec2004/od-20.htm